Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293319 · ClinicalTrials.gov registry record · Phase 2
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
A Phase 2 study of Neuroblastoma, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 3
- Study locations
NCT00293319 is a Phase 2 study of Neuroblastoma that has completed, run by University of California, San Francisco. The registered enrollment target is 164 participants, below the 237-participant average among 94 other Neuroblastoma trials with a reported enrollment target (31% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00293319, a Phase 2 study of Neuroblastoma, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells. PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.
Conditions Studied
Interventions
- BIOLOGICAL filgrastim
- RADIATION iobenguane I 131
Study Locations (3)
California
- UCSF Comprehensive Cancer Center - San Francisco
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293319
The ClinicalTrials.gov registry entry for NCT00293319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 94 other Neuroblastoma trials with a reported enrollment target (31% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which filgrastim is the first listed.
NCT00293319 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00293319 about?
NCT00293319 is a clinical study titled "131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma". RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells. PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.
What is the current status of trial NCT00293319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2005-04. Estimated completion is 2006-03.
What conditions does trial NCT00293319 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00293319?
The interventions under investigation include: filgrastim (BIOLOGICAL), iobenguane I 131 (RADIATION).
Who is sponsoring clinical trial NCT00293319?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00293319 being conducted?
This trial has 3 study locations across California, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.